LifeArc is pioneering new ways to turn great science into greater patient impact. It brings together a network of partners to tackle specific diseases and directly funds academic and early stage research.
So far, LifeArc’s work has helped to develop four drugs (Keytruda®, Actemra®, Tysabri® and Entyvio®) and a test for antimicrobial resistance.
Our Centre for Therapeutics Discovery in Stevenage takes novel academic targets and generates lead stage small molecules and therapeutic antibodies for indications with unmet medical need. MRCT also wish to complement this drug discovery capability by developing novel diagnostics at our Centre for Lifescience Technology.
The Centre for Diagnostic Development (CDD) in Edinburgh operates at the interface between academic research and the Diagnostic industry. It offers collaborative diagnostic assay development and validation, helping translate early stage diagnostic research through to its commercial exploitation and its use in the clinic.